Ventyx Biosciences Inc [NASDAQ: VTYX] stock went on an upward path that rose over 3.85% on Wednesday, amounting to a one-week price increase of more than 11.34%.
Over the last 12 months, VTYX stock rose by 9.64%. The one-year Ventyx Biosciences Inc stock forecast points to a potential upside of 80.61. The average equity rating for VTYX stock is currently 1.67, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $152.74 million, with 70.67 million shares outstanding and 52.89 million shares in the current float. Compared to the average trading volume of 1.71M shares, VTYX stock reached a trading volume of 4918444 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Ventyx Biosciences Inc [VTYX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VTYX shares is $11.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VTYX stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Ventyx Biosciences Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 12, 2024. The new note on the price target was released on March 12, 2024, representing the official price target for Ventyx Biosciences Inc stock. Previously, the target price had yet another drop from $77 to $8, while Wells Fargo kept a Equal Weight rating on VTYX stock.
The Average True Range (ATR) for Ventyx Biosciences Inc is set at 0.19 The Price to Book ratio for the last quarter was 0.55, with the Price to Cash per share for the same quarter was set at 3.89.
VTYX Stock Performance Analysis:
Ventyx Biosciences Inc [VTYX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.34. With this latest performance, VTYX shares dropped by -6.09% in over the last four-week period, additionally sinking by -22.86% over the last 6 months – not to mention a rise of 9.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VTYX stock in for the last two-week period is set at 48.57, with the RSI for the last a single of trading hit 50.60, and the three-weeks RSI is set at 48.35 for Ventyx Biosciences Inc [VTYX]. The present Moving Average for the last 50 days of trading for this stock 2.25, while it was recorded at 2.02 for the last single week of trading, and 2.80 for the last 200 days.
Insight into Ventyx Biosciences Inc Fundamentals:
Ventyx Biosciences Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 23.52 and a Current Ratio set at 23.52.
Ventyx Biosciences Inc [VTYX] Institutonal Ownership Details
There are presently around $84.63%, or 88.61%% of VTYX stock, in the hands of institutional investors. The top three institutional holders of VTYX stocks are: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with ownership of 5.83 million shares, which is approximately 9.4284%. CITADEL ADVISORS LLC, holding 5.76 million shares of the stock with an approximate value of $$13.3 million in VTYX stocks shares; and CITADEL ADVISORS LLC, currently with $$12.12 million in VTYX stock with ownership which is approximately 8.4872%.
